PremiumThe FlyActuate Therapeutics shares highlights from KOL eventon elraglusib data Actuate Therapeutics Reports Positive Phase 2 Trial Results Promising Clinical Trial Results Justify Buy Rating for Actuate Therapeutics’ Elraglusib PremiumThe FlyCraig-Hallum bullish on Actuate Therapeutics, initiates with a Buy Actuate Therapeutics initiated with a Buy at Craig-Hallum Actuate Therapeutics files to sell 3.9M shares of common stock for holders PremiumThe FlyActuate Therapeutics announces interim Phase 2 data of elraglusib Actuate Therapeutics announces new data from Phase 2 trial of elraglusib Actuate Therapeutics added to Russell 2000 Index 
